Study evaluating Bevacizumab in Combination with Carboplatin and Paclitaxel in Women with Metastatic, Recurrent or Persistent Cervical Cancer

Update Il y a 4 ans
Reference: EUCTR2014-005491-28

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To determine the safety of bevacizumab in combination with carboplatin and paclitaxel therapy for metastatic, recurrent or persistent cervical cancer, as defined by the frequency and severity of gastrointestinal (GI) perforation/fistula, GI-vaginal fistula and genitourinary (GU) fistula events


Inclusion criteria

  • Metastatic, Recurrent or Persistent Cervical Cancer